Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. BioLargo, Inc.
  6. News
  7. Summary
    BLGO   US09065A1007

BIOLARGO, INC.

(BLGO)
Delayed OTC Markets  -  03:57 2022-09-27 pm EDT
0.2601 USD   -3.16%
08/16Biolargo : Achieves 185% Growth to $1.3 Million Revenue for Second Quarter 2022, as Published in Quarterly Report
PU
08/15BIOLARGO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/15BioLargo, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BioLargo : Q2 2022 Earnings Results Webcast and Conference Call on Wednesday, August 17, 2022 - 4 PM Eastern Time

08/12/2022 | 08:55am EDT

WESTMINSTER, CA / ACCESSWIRE / August 12, 2022 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company announced it will host an investor webcast and conference call on Wednesday August 17, 2022, at 1:00 pm Pacific / 4:00 pm Eastern. The event, which will be open to the public, will be held to review the company's financial results for the three and six months ended June 30, 2022, discuss recent milestones and ongoing business initiatives, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/46358
Teleconference Domestic: 888-506-0062
Teleconference International: 973-528-0011
Participant Access Code: 656092

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration: Thursday, August 17, 2023
Teleconference Replay Expiration: Wednesday, August 31, 2022
Teleconference Replay Domestic: 877-481-4010
Teleconference Replay International: 919-882-2331
Replay Passcode: 46358

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo's website at www.biolargo.com/investor-relations.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.



View source version on accesswire.com:
https://www.accesswire.com/711802/BioLargo-Q2-2022-Earnings-Results-Webcast-and-Conference-Call-on-Wednesday-August-17-2022--4-PM-Eastern-Time

Disclaimer

BioLargo Inc. published this content on 12 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2022 12:54:11 UTC.


© Publicnow 2022
All news about BIOLARGO, INC.
08/16Biolargo : Achieves 185% Growth to $1.3 Million Revenue for Second Quarter 2022, as Publis..
PU
08/15BIOLARGO, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
08/15BioLargo, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
CI
08/12Biolargo : Q2 2022 Earnings Results Webcast and Conference Call on Wednesday, August 17, 2..
PU
08/11Biolargo : Secures First PFAS Mitigation Customer and Signs New Channel Partner for PFAS R..
PU
08/05BioLargo Announces Revenue Results for the Second Quarter of 2022
CI
08/05Biolargo : Sets New Quarterly Revenue Record - Form 8-K
PU
08/05Biolargo, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
08/03Biolargo : Sets New Quarterly Revenue Record
PU
06/07Biolargo, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submissi..
AQ
More news
Financials (USD)
Sales 2021 2,53 M - -
Net income 2021 -7,08 M - -
Net Debt 2021 0,17 M - -
P/E ratio 2021 -7,41x
Yield 2021 -
Capitalization 70,5 M 70,5 M -
EV / Sales 2020 12,3x
EV / Sales 2021 21,9x
Nbr of Employees 31
Free-Float 84,5%
Chart BIOLARGO, INC.
Duration : Period :
BioLargo, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Dennis P. Calvert Chairman, President & Chief Executive Officer
Charles K. Dargan Chief Financial Officer
Kenneth Reay Code Director & Chief Science Officer
Joseph L. Provenzano Secretary, Director & Executive VP-Operations
Dennis E. Marshall Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOLARGO, INC.22.57%70
SAUDI BASIC INDUSTRIES CORPORATION-25.00%68 998
AIR LIQUIDE-16.11%58 826
WANHUA CHEMICAL GROUP CO., LTD.-13.21%38 377
ALBEMARLE CORPORATION15.36%31 043
TIANQI LITHIUM CORPORATION1.85%24 368